Novartis logo

Cosentyx (secukinumab) TA card

Information intended for UK healthcare professionals only.

The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd. See bottom of page for full disclaimer.

View Cosentyx (secukinumab) prescribing and adverse event reporting information

Download a PDF of the Guidelines summary card

1 Recommendations

1.1 Secukinumab is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti‑inflammatory drugs (NSAIDs) in adults. It is recommended only if:

  • tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
  • the company provides secukinumab according to the commercial arrangement.

1.2 Assess response to secukinumab after 16 weeks of treatment. Continue treatment only if there is clear evidence of response, defined as:

  • a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre‑treatment value or by 2 or more units and
  • a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

1.3 Take into account any communication difficulties, or physical, psychological, sensory or learning disabilities that could affect responses to the BASDAI and spinal pain VAS questionnaires, and make any appropriate adjustments.

1.4 These recommendations are not intended to affect treatment with secukinumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Reference 

  1. NICE. Secukinumab for treating non-radiographic axial spondyloarthritis. NICE Technology Appraisal Guidance 719. NICE, July 2021. www.nice.org.uk/guidance/ta719 

When NICE recommends a treatment, the NHS must make sure it is available to those people it could help, normally within 3 months of the guidance being issued. 

The production of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals UK Ltd. Novartis Pharmaceuticals UK Ltd has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.

This summary card only displays the concise guidance; readers are strongly advised to refer to the full guidance at www.nice.org.uk/guidance/ta719

©NICE 2021. Technology Appraisal 719. Secukinumab for treating non-radiographic axial spondyloarthritis. Available from www.nice.org.uk/guidance/ta719 All rights reserved. Subject to notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this publication. 

MGP Ltd owns copyright of the Guidelines brand, logo, and the design and format of this summary card. The views and opinions expressed are not necessarily those of Guidelines, its publisher, advisers, or advertisers. 

MLR ID 147195

Date of preparation: August 2021